Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide Injection for Weight Management in Overweight and Obese Adults (China)
CTR20232812Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Sep 2023
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide in Overweight, obesity, type 2 diabetes mellitus (T2DM), hypertension (HTN), dyslipidemia, sponsored by Novo Nordisk. Started Sep 2023; status: completed.
02
Drugs
03
Conditions
Overweightobesitytype 2 diabetes mellitus (T2DM)hypertension (HTN)dyslipidemia
Beyond the preview
Go deeper on CTR20232812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232812.